LabNet AML is a service that puts Italian haematologists specialising in acute myeloid leukaemia (AML) in touch with labs that perform cytogenetic and molecular biology tests, foreseen by the WHO classification and the European LeukemiaNet (ELN). The service is provided via the labnetaml.gimema.it web platform.
Currently, 34 Italian labs, that have been approved for genetic-molecular study of AML have been registered on the LabNet platform.
Italian clinical centres that sign up to this project have the advantage of being able to access standardised diagnostic testing and are also entitled to take part in the scientific projects organised by the network.
The service offers a range of basic genetic and molecular tests and has been set up to study the minimal residual disease (MRD) and the somatic mutations that currently play a significant diagnostic and/or prognostic role in acute myeloid leukaemia.
LabNet AML Labs
There are currently 34 Italian labs that have signed up to the AML LabNet.
To find out more
If you wish to find out more about the LabNet AML project write to labnet.aml@gimema.it
